Benefits and side effects of Dapagliflozin medicine in diabetic patients with kidney disease.
Not Applicable
- Conditions
- Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)Health Condition 2: E112- Type 2 diabetes mellitus with kidney complications
- Registration Number
- CTRI/2022/09/045596
- Lead Sponsor
- Maulana Azad Medical College Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients with diagnosis of CKD with type 2 Diabetes Mellitus with HbA1c <8% who had-
eGFR of 30-60ml/min/1.73m2
Urinary Albumin to Creatinine ratio 200-5000mg/g
2. Patients who are on ACE inhibitors or ARBs for at least 4 weeks before screening.
Exclusion Criteria
1. Patients with Type 1 diabetes, lupus nephritis, Rheumatoid arthritis, Cancer and
Neurodegenerative disorders
2. Patients have received immunosuppressive therapy within 6 months.
3. Pregnant patients and nursing mothers.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method